Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Epigenetic Regulation01:37

Epigenetic Regulation

3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond timing: mobility may be the missing variable in venous thromboembolism prevention after traumatic brain injury.

Proceedings (Baylor University. Medical Center)·2026
Same author

Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics.

Nature cancer·2026
Same author

IL4Rα blockade inhibits proliferation of malignant lymphocytes and the immunosuppressive tumor microenvironment of mycosis fungoides.

Journal for immunotherapy of cancer·2026
Same author

Comparative Transcriptional Profiling of Key Macrophage and Fibroblast Subpopulations in Rheumatoid Arthritis-Associated Lung Disease.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

BPTF is essential for vaccine-induced germinal center B cell responses.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Comprehensive multi-omic profiling of desmoplastic small round cell tumors identifies targetable pathways with therapeutic opportunities.

Molecular cancer research : MCR·2026

Related Experiment Video

Updated: Aug 24, 2025

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.5K

Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer.

Xu Hua1, Yongsheng Li2, Sairahul R Pentaparthi2

  • 1Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer Research
|October 20, 2022
PubMed
Summary
This summary is machine-generated.

Somatic mutations in microRNAs (miRNAs) and their targets significantly alter cancer gene networks. This study identifies driver mutations in miRNA regulatory networks, aiding noncoding biomarker discovery and therapeutic drug design.

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.4K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Experiment Videos

Last Updated: Aug 24, 2025

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.5K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.4K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Area of Science:

  • Genomics
  • Cancer Biology
  • Bioinformatics

Background:

  • Somatic mutations drive cancer, but the role of mutations in microRNAs (miRNAs) and their binding sites is largely unknown.
  • MicroRNAs regulate gene expression, and their dysregulation is implicated in various cancers.

Purpose of the Study:

  • To systematically analyze the impact of mutations in miRNAs and their target sites across 30 cancer types.
  • To build cancer-specific miRNA regulatory networks and identify driver mutations affecting these networks.

Main Methods:

  • Construction of detailed cancer-specific miRNA regulatory networks.
  • Mapping over 3.5 million mutations to miRNA-gene interactions (mGI) across 9,819 cancer samples.
  • Utilizing linear regression to identify driver mutations perturbing miRNA networks.

Main Results:

  • Identified 148 candidate driver mutations significantly affecting miRNA regulatory networks.
  • Observed a mutually exclusive pattern between mutations in miRNAs and their target genes.
  • Found that mutated driver gene targets in 3' UTRs act as tumor suppressors and are downregulated in cancer.

Conclusions:

  • Mutations in noncoding regions, particularly miRNAs and their 3' UTR targets, play a significant role in cancer progression.
  • The developed miRNA-gene interaction map (mGI-map) provides a valuable resource for identifying noncoding biomarkers.
  • Findings support novel therapeutic strategies targeting miRNA regulatory networks for cancer treatment.